The locations will feature end-to-end bioprocessing centers and will be in Shanghai, China and Boston, MA.
Following the successful opening of an end-to-end bioprocessing plant in Martillac, France in 2012, MilliporeSigma announced on Jan. 10, 2016 that it will open two more bioprocessing locations, one of which will be in China and the other in Boston, Massachusetts. The new locations will offer cell-line development services, process development expertise, and non-GMP clinical production services. The main difference between the new locations and the existing Martillac site is that the France location is a GMP facility that manufactures clinical-stage batches. The France site is the main biodevelopment center worldwide, according to Karen Tiano, head of media relations at MilliporeSigma.
According to a company press release, the Boston and Shanghai sites are non-GMP. The locations will feature the full suite of MilliporeSigma technologies. The suite includes single-use, sterile connectors, single-use disposable modules for viral clearance, tangential flow filtration cassettes for filtration, and a gene-editing technology to confer viral resistance to Chinese hamster ovary (CHO) cell lines.
Source: MilliporeSigma
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.